Next Big Opportunity -> More News Soon / Buyout Possible 11-Jul-08 01:33 pm .... Stock is headed to $8 -$10 range ....
... In this market environment, biotech stocks are a haven of safety. Expect institutions to start accumulating stock in AKRX.
... Shorts have been covering but still have 10.8 million still to cover (20% of the float) short ratio 43.5.
... Financier Steven Cohen Reports 5.6 Percent Passive Stake in Akorn
... Soleil Securities Group is out with a research note this morning highlighting reasons why it would be "aggressive buyers" of Akorn (Nasdaq: AKRX) at current levels. The firm maintains its Buy rating and $8 price target on the stock.
... Approval of Akten Ophthalmic Gel 3.5% SOON
... As the FDA only required paperwork and labeling information on AKTEN and NO clinical data, expect an approval soon. AKTEN is far more important than Vancomycin.
... Company raised revenue forecasts for quarter and full year